Loading
A phase 3 trial of Apalutamide and Bicalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS is a phase 3 interventional study registered as NCT02531516 by Aragon Pharmaceuticals, Inc., with 1503 participants enrolled, started 2015-11-19 and due to reach its primary completion in 2027-03-01. Interventions recorded: Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist) and 74-80 Grays (units of radiation).
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Bicalutamide, Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.